Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

0.0933 +0.0047 (+5.30%)
Streaming Delayed Price Updated: 1:32 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 555,194
Open 0.0948
Bid (Size) 0.0926 (100)
Ask (Size) 0.0949 (500)
Prev. Close 0.0886
Today's Range 0.0904 - 0.0980
52wk Range 0.0855 - 2.100
Shares Outstanding 15,859,280
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
From Rosen Law Firm
Via Business Wire
These stocks are moving in today's after hours session ↗
Via Chartmill

Performance

YTD
-83.7%
-83.7%
1 Month
-9.4%
-9.4%
3 Month
-52.2%
-52.2%
6 Month
-89.7%
-89.7%
1 Year
-94.9%
-94.9%

More News

Read More
News headline image
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
From Propanc Biopharma, Inc.
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
Unusual volume stocks in Friday's session ↗
Via Chartmill
News headline image
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
From Propanc Biopharma, Inc.
Via GlobeNewswire
Top movers in Thursday's session ↗
Via Chartmill
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
From Propanc Biopharma, Inc.
Via GlobeNewswire
Which stocks are moving after the closing bell on Friday? ↗
Via Chartmill
News headline image
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Shareholder Update
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline
From Propanc Biopharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Propanc Biopharma, Inc. - Common Stock publicly traded?
Yes, Propanc Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Propanc Biopharma, Inc. - Common Stock trade on?
Propanc Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Propanc Biopharma, Inc. - Common Stock?
The ticker symbol for Propanc Biopharma, Inc. - Common Stock is PPCB on the Nasdaq Stock Market
What is the current price of Propanc Biopharma, Inc. - Common Stock?
The current price of Propanc Biopharma, Inc. - Common Stock is 0.0933
When was Propanc Biopharma, Inc. - Common Stock last traded?
The last trade of Propanc Biopharma, Inc. - Common Stock was at 05/11/26 01:32 PM ET
What is the market capitalization of Propanc Biopharma, Inc. - Common Stock?
The market capitalization of Propanc Biopharma, Inc. - Common Stock is 1.48M
How many shares of Propanc Biopharma, Inc. - Common Stock are outstanding?
Propanc Biopharma, Inc. - Common Stock has 1M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.